{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:41:35Z","timestamp":1772808095534,"version":"3.50.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,4,11]]},"DOI":"10.1001\/jama.2023.4405","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:02:55Z","timestamp":1681225375000},"page":"1155","source":"Crossref","is-referenced-by-count":3,"title":["Lack of Benefit of Renin-Angiotensin System Inhibitors in COVID-19"],"prefix":"10.1001","volume":"329","author":[{"given":"Matthew M. Y.","family":"Lee","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"17","key":"jed230019r1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19.","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N Engl J Med"},{"key":"jed230019r2","article-title":"Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support\u2013free days in patients hospitalized with COVID-19: a randomized clinical trial.","author":"Writing Committee for the REMAP-CAP Investigators","journal-title":"JAMA"},{"key":"jed230019r3","article-title":"Renin-angiotensin system modulation with synthetic angiotensin (1-7) and angiotensin II type 1 receptor-biased ligand in adults with COVID-19: two randomized clinical trials.","author":"Self","journal-title":"JAMA"},{"issue":"17","key":"jed230019r4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026143","article-title":"Renin-angiotensin system inhibitors in patients with COVID-19: a meta-analysis of randomized controlled trials led by the International Society of Hypertension.","volume":"11","author":"Gnanenthiran","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"jed230019r5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072175","article-title":"Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.","volume":"379","author":"Jardine","year":"2022","journal-title":"BMJ"},{"issue":"3","key":"jed230019r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2735","article-title":"Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial.","volume":"5","author":"Puskarich","year":"2022","journal-title":"JAMA Netw Open"},{"key":"jed230019r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial.","volume":"37","author":"Duarte","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"6","key":"jed230019r8","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.v75.6","article-title":"Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: a randomised clinical trial.","volume":"75","author":"Nouri-Vaskeh","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"3","key":"jed230019r9","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40121-021-00453-3","article-title":"Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized covid-19 patients with mild hypoxemia.","volume":"10","author":"Geriak","year":"2021","journal-title":"Infect Dis Ther"},{"key":"jed230019r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2022.100968","article-title":"COVIDMED: an early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients.","volume":"29","author":"Freilich","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"3","key":"jed230019r11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","article-title":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial.","volume":"325","author":"Lopes","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"jed230019r12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","article-title":"Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.","volume":"9","author":"Bauer","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"jed230019r13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-2600(20)30558-0","article-title":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.","volume":"9","author":"Cohen","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"11","key":"jed230019r14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/ajh\/hpab111","article-title":"Effects of renin-angiotensin-aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: a randomized triple-blind clinical trial.","volume":"34","author":"Najmeddin","year":"2021","journal-title":"Am J Hypertens"},{"key":"jed230019r15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ahj.2022.01.015","article-title":"A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.","volume":"247","author":"Sharma","year":"2022","journal-title":"Am Heart J"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2803540\/jama_lee_2023_ed_230019_1680895646.85958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:02:59Z","timestamp":1681225379000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2803540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":15,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,4,11]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.4405","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}